Atossa Therapeutics (NASDAQ:ATOS) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Atossa Therapeutics (NASDAQ:ATOS) from a hold rating to a sell rating in a report issued on Monday morning.

Other equities research analysts have also issued research reports about the company. HC Wainwright lifted their price objective on Atossa Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ascendiant Capital Markets lifted their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th.

Atossa Therapeutics Stock Down 6.3 %

NASDAQ ATOS opened at $1.20 on Monday. Atossa Therapeutics has a 52-week low of $0.70 and a 52-week high of $2.31. The business’s 50-day moving average price is $1.44 and its 200 day moving average price is $1.37. The firm has a market cap of $150.96 million, a P/E ratio of -5.82 and a beta of 1.23.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Atossa Therapeutics by 280.9% during the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after purchasing an additional 123,683 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after purchasing an additional 44,762 shares during the last quarter. XTX Topco Ltd raised its position in shares of Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. State Street Corp raised its position in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after purchasing an additional 69,180 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $75,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.